Cantex Pharmaceuticals, Inc.
Developing novel treatments of inflammatory diseases and cancer
Developing novel treatments of inflammatory diseases and cancer
Cantex Pharmaceuticals, Inc. is a pharmaceutical company founded in 2007, focusing on the development of novel treatments for inflammatory diseases and cancer. The company's mission revolves around addressing the pressing medical needs across a spectrum of conditions, including cancer, complications of COVID-19 infection, and pulmonary inflammatory diseases. Cantex Pharmaceuticals, Inc. operates within the Biopharma, Biotechnology, and Pharmaceutical industries.
The latest investment in Cantex Pharmaceuticals, Inc. amounted to $3.27M, structured as Debt Financing, and took place on April 22, 2014. The investors involved in this financing round were not specified.
As Cantex Pharmaceuticals, Inc. continues its pursuit of groundbreaking medical treatments, the recent financial backing underscores a vote of confidence in the company's vision and potential impact within the healthcare and pharmaceutical sectors.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Debt Financing | $3.27M | - | 22 Apr 2014 | |
| Series B | $19.00M | 4 |
|
05 Sep 2006 |
No recent news or press coverage available for Cantex Pharmaceuticals, Inc..
We care about your data, and we'd love to use cookies make your experience better.
